After the BioNTech share, the Moderna share could next move into the spotlight when it comes to COVID-19 vaccines: The US biotech company is expected to publish the first data on the clinical study with its vaccine candidate against the pathogen of the corona pandemic in the coming days. It has now been announced that the rolling review approval process for the mRNA-1273 vaccine has been started in Switzerland. Like the BioNTech and Pfizer duo, Moderna is likely to apply for the approval process for the vaccine in the USA in the near future. Like BioNTech’s BNT162, Moderna’s mRNA-1273 could receive emergency approval in 2020.
Moderna’s share price, which had since fallen from its all-time high of $ 95.21 to $ 54.21 (reached on September 8) in mid-July, has recovered to as much as $ 87.93 in the last two months or so, the Biotech shares on NASDAQ yesterday. The development here is somewhat reminiscent of the BioNTech share, which also rose in the run-up to the publication of the clinical test data. It remains to be seen whether the rest of the course will also be a blueprint. As a reminder: Immediately after the good test data was announced, BioNTech shares shot up to 115 dollars and thus a new all-time high, but could not keep the break above the previous top at 105 dollars stable in the following days.
Moderna’s share price is not far from its own all-time high of $ 95.21. In terms of the chart, upstream hurdles appear at 87.00 / 88.37 dollars and 90.85 dollars. Before the trading session in the US, the biotech share tends to be weak today, the current indication is trading at $ 86.13 below yesterday’s NASDAQ closing price. At 83.83 / 84.29 dollars and below 81.37 dollars, the paper would encounter the first technical support when prices drop.